Table 2 Effect of test compounds on egg albumin protein denaturation
Design of treatment | Concentration (μg/ml) | Mean ± SEM | % inhibition |
|---|---|---|---|
Group-I (control) | – | 1.2 ± 0.059 | – |
Group-II (diclo) | 50 | 0.55 ± 0.015* | 54.16 |
100 | 0.49 ± 0.040** | 59.16 | |
150 | 0.42 ± 0.033** | 65.00 | |
200 | 0.40 ± 0.080** | 66.66 | |
250 | 0.36 ± 0.032** | 70.00 | |
Group-III (G1) | 50 | 0.78 ± 0.047 | 35.00 |
100 | 0.78 ± 0.048* | 35.00 | |
150 | 0.78 ± 0.047* | 35.00 | |
200 | 0.72 ± 0.006** | 40.00 | |
250 | 0.71 ± 0.002** | 40.00 | |
Group-IV (G2) | 50 | 0.71 ± 0.002 | 40.83 |
100 | 0.71 ± 0.008 | 40.83 | |
150 | 0.71 ± 0.009* | 40.83 | |
200 | 0.70 ± 0.008* | 41.66 | |
250 | 0.70 ± 0.006** | 41.66 | |
Group-V (G3) | 50 | 0.82 ± 0.014 | 31.66 |
100 | 0.80 ± 0.011* | 33.33 | |
150 | 0.75 ± 0.003* | 37.50 | |
200 | 0.73 ± 0.009** | 39.00 | |
250 | 0.61 ± 0.004** | 49.16 |